- We will send in 10–14 business days.
/images/books/13512140/9786205387634.jpg)
- Author: Hugo Barcia M
- Publisher: Our Knowledge Publishing
- ISBN-10: 6205387638
- ISBN-13: 9786205387634
- Format: 15.2 x 22.9 x 0.3 cm, softcover
- Language: English
- SAVE -10% with code: EXTRA
Palliative Use of Inotropics in End-Stage Heart Failure (e-book) (used book) | bookbook.eu
Reviews
Description
On average 1% of the population over 40 years of age acquires an initial stage of heart failure and this percentage doubles every 10 years, representing 10% in those over 70 years of age. This implies the great impact of the disease in relation to its incidence and prevalence; it currently affects more than 6 million adults in the United States, and 8 million patients are projected by 2030.Throughout the life of the heart failure patient it is usually necessary to apply a series of complex and invasive treatments, which however in advanced stages of the disease are less effective.A review of the American College of Cardiology / American Heart Association (ACC / AHA) Guidelines emphasizes palliative inotropic therapy as part of an overall plan to improve quality of life in this group of patients. This proposes a major challenge that diverts us from the main focus of these drugs; that is why through this review we propose that inotropic drugs would have a place as palliative treatment in end-stage heart failure.
EXTRA 10 % discount with code: EXTRA
The promotion ends in 15d.11:18:52
The discount code is valid when purchasing from 10 €. Discounts do not stack.
- Author: Hugo Barcia M
- Publisher: Our Knowledge Publishing
- ISBN-10: 6205387638
- ISBN-13: 9786205387634
- Format: 15.2 x 22.9 x 0.3 cm, softcover
- Language: English English
On average 1% of the population over 40 years of age acquires an initial stage of heart failure and this percentage doubles every 10 years, representing 10% in those over 70 years of age. This implies the great impact of the disease in relation to its incidence and prevalence; it currently affects more than 6 million adults in the United States, and 8 million patients are projected by 2030.Throughout the life of the heart failure patient it is usually necessary to apply a series of complex and invasive treatments, which however in advanced stages of the disease are less effective.A review of the American College of Cardiology / American Heart Association (ACC / AHA) Guidelines emphasizes palliative inotropic therapy as part of an overall plan to improve quality of life in this group of patients. This proposes a major challenge that diverts us from the main focus of these drugs; that is why through this review we propose that inotropic drugs would have a place as palliative treatment in end-stage heart failure.
Reviews